ORIGINAL ARTICLE


Acesso aberto Revisado por pares

4601

Visualizações

Elevated plasma concentrations of S100 calcium-binding protein B and tumor necrosis factor alpha in children with autism spectrum disorders

Elevated plasma concentrations of S100 calcium-binding protein B and tumor necrosis factor alpha in children with autism spectrum disorders

Selin Aktan Guloksuz1, Osman Abali2, Esin Aktas Cetin3, Sema Bilgic Gazioglu3, Gunnur Deniz3, Abdurrahman Yildirim4, Ivana Kawikova5, Sinan Guloksuz6,7, James F. Leckman1

Vol.39 Issue 3/2017: 195-200

ABSTRACT

OBJECTIVE: To investigate plasma concentrations of S100B (a calcium-binding protein derived primarily from the glia) and inflammatory cytokines in children with autism and the relationship between S100B and cytokine concentrations. METHODS: Plasma levels of S100B, tumor necrosis factor alpha (TNF-α), interferon gamma, interleukin (IL)-1β, IL-4, IL-6, IL-10, and IL-17A were measured in 40 unmedicated children with autism and 35 normally developing healthy children. The severity of autism was assessed using the Childhood Autism Rating Scale (CARS). RESULTS: Concentrations of both S100B and TNF-α were higher in children with autism before and after adjusting for a priori-selected confounders (age, sex, and body mass index). S100B concentrations were higher in children with severe autism compared to children with mild-moderate autism. However, this association remained as a trend after adjusting for confounders. S100B concentrations correlated positively with TNF-α concentrations. CONCLUSION: Our findings showing an increase in peripheral concentrations of S100B and TNF-α provide limited support to the hypothesis about the roles of altered immune function and S100B in autism spectrum disorder (ASD). Studies of larger numbers of well-characterized individuals with ASD are needed to clarify the potential role of the immune system in the pathophysiology of this disorder.

Keywords: Autism; inflammation; glia; tumor necrosis factor; cytokine; S100B


THE CONTENT OF THIS ARTICLE IS NOT AVAILABLE FOR THIS LANGUAGE.


© 2026 All rights reserved